2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2296 TNFRSF17 (B Cell Maturation Antigen, BCMA) alterations and downstream compensatory pathway activation following BCMA-directed CAR T-cell and bispecific T-cell engagers in multiple myeloma

Matthew James Rees, MD, Surendra Dasari, Associate Professor2, Saurabh Zanwar, MBBS, MD3, Amit Khot, MBBS, MD, MRCP (UK), FRCPath, FRACP4, David Dingli, MD, PhD5, Moritz Binder, MD, MPH6, Taxiarchis Kourelis, MD7, Wilson Gonsalves, MD8, Angela Dispenzieri, MD9, Morie Gertz, MD10, Rahma Warsame, MD11, Joselle M Cook, M.D.12, Francis Buadi, MD13, Dragan Jevremovic, MD PhD14, S. Vincent Rajkumar, MD15, Prashant Kapoor, MD16, Yi Lin Jr, MD, PhD17, Shaji Kumar, MD18
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States

Background: BCMA-directed CAR T-cell and T-cell engagers (TCE) produce high response rates in relapsed multiple myeloma, but most patients eventually progress. Prior work has reported TNFRSF17 alterations leading to BCMA antigen escape in up to 43% of TCE and 20% of CAR T-cell progressions (Lee Nat Med 2023). Whether this frequency is generalisable, and whether alterations in pathways downstream of BCMA contribute to antigen-loss-independent resistance by promoting resistance to T-cell-mediated cytotoxicity, remains unclear.

Methods: Whole-exome sequencing was performed on 32 paired pre- and post-treatment bone marrow samples at the time of disease progression from 15 patients (5 CAR T, 10 TCE); two patients received both BCMA-directed CAR T and TCE. Patients were selected on the basis of disease progression, and bone marrow sample availability. Variants were filtered for depth, allele frequency and predicted pathogenicity according to SIFT and PolyPhen. Coding mutations and copy-number status of TNFRSF17 were assessed. Deleterious or loss-of-function (LOF) variants in NF-κB, PI3K-AKT-mTOR, MAPK/ERK and JNK/p38 pathways were classified as pre-existing (baseline variant allele frequency [VAF] ≥0.05), acquired (unique to post-treatment samples) or enriched (change in VAF ≥20% post-treatment).

Results: The median patient age was 66-years, 60% were male, 80% triple-class refractory, and a median of 5 prior lines of treatment. All post-treatment samples were obtained at the time of progressive disease. Best responses to CAR T-cell therapy were sCR/CR (n=2), VGPR (n=3), and PD (n=1). Best responses to TCE were sCR/CR (n=5), VGPR (n=1), PR (n=2), SD (n=2), and PD (n=1). The median bone marrow plasma cell (BMPC) burden of samples was 55% (IQR = 30-80) with a mean coverage depth of 208x. Bone marrow samples included CD138+ sorted (n=13), unsorted cryopreserved (n=5, median BMPC=30%, range 5-95%), and trephine-extracted DNA (n=14, median BMPC=65%, range 25-95%). TNFRSF17 genomic alteration was infrequent. TNFRSF17 coding mutations occurred in only one post-TCE sample (concurrent frameshift p.Thr92ArgfsTer9 and missense p.Pro23Ser). Heterozygous copy-number loss was seen in two additional TCE-treated patients; no biallelic loss and no CAR T-associated TNFRSF17 alterations were identified. In contrast, deleterious or LOF variants in BCMA downstream pathways were universal in pre-treatment samples (109 unique variants; median 6 per patient, range 1–21). Recurrent pre-existing events included DUSP5 p.Ala220Met (12/15 patients), BRAF kinase-domain mutations (3 patients, including p.Val640Glu, p.Glu626Lys and p.Gly504Arg), NFKBIA LOF variants (2 patients: p.Ter318SerextTer5 & p.Gln271HisfsTer2) and MAP3K9 alterations (three patients). One patient harboured a pre-existing CYLD nonsense mutation. Eleven of 15 patients acquired new deleterious or LOF variants in downstream pathways after therapy (53 unique events; median 1 per patient). The PI3K-AKT-mTOR axis accounted for the largest number of acquired variants (27 events, 9 patients), including alterations in FGFR-family genes, ERBB2, AKT2, RICTOR and IRS2. Acquired alterations in CYLD were observed in two patients (2 post-TCE p.Thr521IlefsTer6 & p.Leu423Phe). Additional convergent acquired events included identical TAB3 frameshift insertion and deletion pairs in two patients, and identical VCAM1 missense variants in two patients. MAPK/ERK acquisitions included activating NRAS, KRAS and BRAF mutations. Clonal enrichment of pre-existing variants (ΔVAF ≥20%) was more pronounced after TCE (10 variants, 3 patients) than after CAR T (1 variant, 1 patient) and was dominated by MAPK-pathway events, including known activating BRAF and KRAS mutations.

Conclusions: In this paired series, antigen escape via TNFRSF17/BCMA alteration was uncommon. Pre-existing, acquired and clonally enriched pathogenic variants in the NF-κB, PI3K-AKT-mTOR and MAPK cascades instead emerged as a recurrent finding after both CAR T-cell and TCE therapy, suggesting that deregulation of BCMA-downstream signalling pathways promotes resistance to BCMA-directed immunotherapy. For NF-κB pathway alterations in particular, this may be via enhanced anti-apoptotic signalling that confers resistance to T-cell cytotoxicity despite preserved BCMA expression (Jung Blood 2024).

Matthew James Rees, MD: No relevant conflicts of interest to declare.